Zymeworks Inc. (ZYME)
| Market Cap | 1.72B +73.4% |
| Revenue (ttm) | 81.26M -13.0% |
| Net Income | -102.66M |
| EPS | -1.36 |
| Shares Out | 71.59M |
| PE Ratio | n/a |
| Forward PE | 22.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 444,592 |
| Open | 23.81 |
| Previous Close | 23.76 |
| Day's Range | 23.70 - 24.21 |
| 52-Week Range | 11.51 - 29.75 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 39.33 (+63.53%) |
| Earnings Date | Aug 6, 2026 |
About ZYME
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead pr... [Read more]
Financial Performance
In 2025, Zymeworks's revenue was $105.97 million, an increase of 38.87% compared to the previous year's $76.30 million. Losses were -$81.13 million, -33.88% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ZYME stock is "Strong Buy." The 12-month stock price target is $39.33, which is an increase of 63.53% from the latest price.
News
Zymeworks management to meet with B. Riley
Meeting to be held in San Francisco on July 28 and in Los Angeles on July 29 hosted by B. Riley.
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipe...
Zymeworks price target raised to $31 from $28 at Truist
Truist raised the firm’s price target on Zymeworks (ZYME) to $31 from $28 and keeps a Buy rating on the shares as part of a broader research note updating the…
Zymeworks price target raised to $37 from $34 at Wells Fargo
Wells Fargo raised the firm’s price target on Zymeworks (ZYME) to $37 from $34 and keeps an Overweight rating on the shares. The firm views the acquisition of Theravance Biopharma…
Zymeworks price target raised to $37 from $35 at Citi
Citi raised the firm’s price target on Zymeworks (ZYME) to $37 from $35 and keeps a Buy rating on the shares. The firm says the Theravance Biopharma (TBPH) acquisition adds…
Zymeworks Transcript: M&A announcement
The acquisition of Theravance Biopharma adds a durable, cash-generative COPD asset, YUPELRI, and multiple value streams to the portfolio, funded through non-recourse financing and expected to be accretive post-closing. Integration will focus on cost synergies and leveraging existing infrastructure.
Zymeworks Press release: M&A announcement
Zymeworks issued a press release on June 29, 2026, disclosing material business information to investors.
Zymeworks Slides: M&A announcement
Zymeworks has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B
Shares in biotechnology company Zymeworks ($ZYME) were off color in pre-market trading today despite agreeing a near $1 billion deal to buy Theravance Biopharma ($TBPH). Cash Flows From Deal Vancouver...
Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash
Theravance Biopharma (TBPH) announced that it has entered into a definitive agreement pursuant to which Zymeworks (ZYME) will acquire the company for $17.00 per share in cash, representing an equity…
Zymeworks strikes $929 million deal for Theravance Biopharma
Drugmaker Zymeworks said on Monday it will buy Theravance Biopharma in a $929 million deal.
Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M
Zymeworks (ZYME) announced it has entered into a definitive agreement to acquire Theravance Biopharma (TBPH). This proposed acquisition adds YUPELRI, the first and only nebulized, once-daily, long-act...
Zymeworks to acquire Theravance Biopharma for $17.00 per share
06:00 EDT Zymeworks (ZYME) to acquire Theravance Biopharma (TBPH) for $17.00 per share
Zymeworks to Acquire Theravance Biopharma, Inc.
VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing ...
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody drug discovery. VANCOUVER, BC, June 18, 2026 /PRNewsw...
Zymeworks presents new clinical data on Phase 1 study of ZW191
Zymeworks (ZYME) presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha-targeting antibody-drug conjugate, ADC, at the Euro...
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipe...
Zymeworks assumed with a Buy at Truist
Truist assumed coverage of Zymeworks (ZYME) with a Buy rating with a price target of $28, down from $40. The firm sees the stock as a balanced sector play, leveraging…
Zymeworks Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a robust oncology pipeline, with zanidatamab poised for broad adoption pending August approval and major expansion opportunities in breast cancer. ZW191 and ZW251 are progressing in early trials, while the R&D strategy is shifting toward novel multi-specifics and custom payloads.
Zymeworks authorizes share repurchase program of up to $125M
Zymeworks (ZYME) announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to $125M of its outstanding common stock. “The authorization…
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipel...
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipel...
Zymeworks reports Q1 EPS (59c), consensus (10c)
Reports Q1 revenue $2.4M, consensus $35.58M. The revenue decrease was driven mainly by the achievement of non-recurring clinical milestone payments in 2025, as well as continued declines in developmen...
Zymeworks Earnings Call Transcript: Q1 2026
Q1 2026 saw regulatory progress for zanidatamab, strong cash reserves, and pipeline advances in ADCs, with revenue down year-over-year due to non-recurring milestones. Share repurchases and anticipated milestone payments support long-term funding and value creation.
Zymeworks Earnings release: Q1 2026
Zymeworks released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.